健康大鼠注射钆匹醇、钆特酸或钆布醇人等效剂量后5个月内总体钆暴露比较
在健康雌性大鼠中单次静脉注射钆匹醇(0.3 mmol/kg)、钆特酸(0.6 mmol/kg)或钆布醇(0.6 mmol/kg)人等效剂量后,用ICP-MS测定组织钆浓度并计算5个月AUC,钆匹醇总体钆暴露较钆特酸和钆布醇分别低25%和40%,但股骨矿物部分钆暴露更高或相当、骨髓更低。
要点
- 钆匹醇人等效剂量下5个月总体钆暴露较钆特酸低25%、较钆布醇低40%。
- 血浆、中枢神经、周围神经、脾、皮肤、肝、肾的钆暴露均降低。
- 股骨矿物部分钆暴露钆匹醇更高或相当,骨髓则更低。
核心结论
- 在本实验条件下,大鼠注射钆匹醇人等效剂量后5个月总体钆暴露较钆特酸和钆布醇分别低25%–40%。
研究设计与样本
- 健康9周龄雌性Sprague-Dawley大鼠随机分为4组,每组每时间点n=10,单次静脉注射钆特酸0.6 mmol/kg、钆布醇0.6 mmol/kg、钆匹醇0.3 mmol/kg或生理盐水对照,于注射后1天、1周、1个月或5个月处死,取中枢神经、周围神经、排泄器官及骨等组织,以电感耦合等离子体质谱测定总钆浓度,计算首末时间点间AUC估算5个月总体暴露,全程盲法。
诊断标准与关键数值
- 钆匹醇5个月总体钆暴露较钆特酸低25%。
- 钆匹醇5个月总体钆暴露较钆布醇低40%。
- 血浆、中枢神经(小脑、皮层脑、皮层下脑、脑干、脊髓)、周围神经(脊神经节、坐骨神经、足垫)、脾、皮肤、肝、肾的钆暴露在观察期内降低。
- 股骨骨干和骨骺等矿物部分钆暴露钆匹醇高于或相当于钆布醇和钆特酸,骨髓则更低。
- 各组织残留钆为注射剂量的10^-6(中枢神经)至10^-3(肾、矿物骨)%/g组织。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: Gadopiclenol is a high relaxivity macrocyclic and nonionic Gadolinium-Based Contrast Agent (GBCA) for central nervous system (CNS) and Body MRI, approved in September 2022 by the Food and Drug Administration and in December 2023 by the European Medicine Agency and others European health authorities. Gadopiclenol is currently indicated at half gadolinium-dose (0.05 mmol/kg body weight) compared to the other nonspecific marketed GBCAs. This study aims to evaluate the impact of this gadolinium (Gd) dose reduction in terms of overall Gd body exposure. Requiring tissue samples at different times, this information is only accessible through animal experiment. In this study, the Gd exposure over a 5-month period was evaluated in healthy rats after a single injection of gadopiclenol in comparison with 2 other macrocyclic GBCAs approved for human use, gadobutrol and gadoterate, all administered at their respective human equivalent dose (HED).
MATERIAL AND METHODS: Healthy 9-week-old female Sprague-Dawley rats were randomly allocated to 4 groups, receiving 1 single intravenous injection of gadoterate (Dotarem, 0.6 mmol/kg), gadobutrol (Gadovist, 0.6 mmol/kg), gadopiclenol (Elucirem, 0.3 mmol/kg), or saline (control group). Animals were euthanized 1 day (D1), 1 week (W1), 1 month (M1), or 5 months (M5) after the injection (n = 10/group and time-point). Selected tissues (including central [CNS] and peripheric nervous system [PNS] organs, excretion organs, bone) were collected for subsequent total Gd determination with inductively coupled plasma mass spectrometry. Based on Gd concentration measurements at these different time points, the 5 months overall exposure to Gd in each organ was estimated by calculating the area under the curve (AUC), between the first and the last time point. The whole study was performed in a blinded manner.
RESULTS: Following gadopiclenol administration to rats at the HED, overall Gd exposure over 5 months was found to be 25% to 40% lower compared to gadoterate and gadobutrol, respectively. Organ by organ, Gd exposure reduction is observed over the studied period in the plasma, CNS (cerebellum, cortical brain, subcortical brain, brain stem, spinal cord), PNS (spinal nodes, sciatic nerve, footpads), the spleen, the skin, the liver, and the kidney. In the femur, the Gd exposure after gadopiclenol administration was higher or equivalent compared to gadobutrol and gadoterate in the mineral parts of the bone (diaphysis and epiphysis), but lower in the bone marrow. Residual Gd found in each tissue studied is extremely low relative to the injected dose), with values ranging from 10 -6 (CNS) to 10 -3 (kidney, mineral bone) % injected dose/g of organ.
CONCLUSIONS: Under our experimental conditions, the overall measured Gd exposure over 5 months following gadopiclenol injection in rats at the HED is 25-40% lower than that after gadoterate and gadobutrol injections, respectively.
引用
- Rasschaert M, Couloumy E, Renard E, et al. Overall Gadolinium Exposure Within the First 5 Months After Injection of Human Equivalent Doses of Gadopiclenol, Gadoterate, or Gadobutrol in Healthy Rats. Invest Radiol. 2025. PMID: 40384088. doi:10.1097/RLI.0000000000001194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。